iShares Biotechnology ETF (NASDAQ:IBB) Holdings Lowered by Patten Group Inc.

Patten Group Inc. trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 26.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,029 shares of the financial services provider’s stock after selling 721 shares during the quarter. Patten Group Inc.’s holdings in iShares Biotechnology ETF were worth $268,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IBB. BNP Paribas Financial Markets raised its holdings in shares of iShares Biotechnology ETF by 29.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after purchasing an additional 538,899 shares in the last quarter. Commerce Bank raised its holdings in shares of iShares Biotechnology ETF by 1.8% in the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock worth $108,234,000 after purchasing an additional 12,921 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC raised its holdings in shares of iShares Biotechnology ETF by 2.5% in the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares in the last quarter. Finally, Gray Foundation raised its holdings in shares of iShares Biotechnology ETF by 25.2% in the 4th quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock worth $21,798,000 after purchasing an additional 33,179 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $134.36 on Wednesday. The company’s 50 day simple moving average is $135.92 and its 200 day simple moving average is $140.53. iShares Biotechnology ETF has a 12 month low of $123.60 and a 12 month high of $150.57. The company has a market capitalization of $6.35 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.